Larimar Therapeutics, Inc. (LRMR): Price and Financial Metrics
LRMR Price/Volume Stats
| Current price | $6.46 | 52-week high | $13.68 |
| Prev. close | $6.40 | 52-week low | $2.18 |
| Day low | $6.35 | Volume | 243,900 |
| Day high | $6.88 | Avg. volume | 561,750 |
| 50-day MA | $9.04 | Dividend yield | N/A |
| 200-day MA | $5.17 | Market Cap | 412.15M |
LRMR Stock Price Chart Interactive Chart >
Larimar Therapeutics, Inc. (LRMR) Company Bio
Larimar Therapeutics, Inc. operates as a biotech company. The Company develops and discovers treatments for complex rare diseases such as protein replacement therapy. Larimar Therapeutics serves customers in the State of Pennsylvania.
Latest LRMR News From Around the Web
Below are the latest news stories about LARIMAR THERAPEUTICS INC that investors may wish to consider to help them evaluate LRMR as an investment opportunity.
With 45% ownership, Larimar Therapeutics, Inc. (NASDAQ:LRMR) has piqued the interest of hedge funds investorsKey Insights Given the large stake in the stock by institutions, Larimar Therapeutics' stock price might be vulnerable... |
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial ResultsCompleted full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial; based on blinded observations during the dosing period, there were no serious adverse events in either the CTI-1601 (nomlabofusp) or placebo groups.Top-line safety, pharmacokinetic, and frataxin data from the Phase 2 trial now expected in Q1 2024, refined from H1 2024Initiation of open label extension (OLE) trial with 25 mg daily dosing of nomlabofusp remains on track for Q1 2024; |
Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology ConferenceBALA CYNWYD, Pa., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference, taking place in New York, NY from November 6 - 7, 2023. Details on the fireside chat can be |
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of DirectorsBALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P. to the Company’s Board of Directors, effective today. Dr. Sherman, currently Executive Vice President, Chief Medical Officer (CMO) at Horizon Therapeutics Public Limited Company, has over 20 years of executive experience in |
Larimar Therapeutics to Present at the Citi 18th Annual BioPharma ConferenceBALA CYNWYD, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a panel discussion and 1x1 investor meetings at the Citi 18th Annual BioPharma Conference, taking place in Boston, MA from September 5 - 7, 2023. Details on the panel discussion can be found below. Title: Rare Neurological DiseasesDat |
LRMR Price Returns
| 1-mo | -14.78% |
| 3-mo | 36.58% |
| 6-mo | 142.86% |
| 1-year | 43.24% |
| 3-year | -54.98% |
| 5-year | -79.05% |
| YTD | 41.98% |
| 2023 | 10.17% |
| 2022 | -61.72% |
| 2021 | -49.60% |
| 2020 | 60.74% |
| 2019 | -77.58% |
Loading social stream, please wait...